SCHEDULE: Coastlands Capital Acquires 9.72% Stake in iBio, Inc.

Investment firm Coastlands Capital LP, along with affiliated entities and its control person Matthew D. Perry, has reported beneficial ownership of 9.72% of iBio, Inc.'s common stock.

Summary

• Coastlands Capital LP and its related entities (Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC) and Matthew D. Perry have jointly filed a Schedule 13G.
• They collectively beneficially own 6,247,738 shares of iBio, Inc. common stock.
• This represents 9.72% of the outstanding common stock.
• The filing is based on 64,307,256 shares outstanding as of August 27, 2026, as per iBio's Form 10-K filed on August 28, 2026.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest and do not form a group for the purpose of this filing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake acquisition by an investment entity. The lack of aggressive language or immediate strategic implications suggests a measured approach.

Positives

• Significant stake acquisition by an investment entity, potentially signaling confidence in the company's future.
• The reporting persons have shared voting and dispositive power over 6,247,738 shares, indicating a coordinated investment strategy.
• The filing is made under Rule 13d-1(b), suggesting the acquisition is part of ordinary business operations and not for control-changing purposes.

Negatives

• The filing does not provide details on the acquisition cost or the specific timing of the purchases.
• The beneficial ownership is limited to 9.72%, with pre-funded warrants and warrants held in excess of a 4.99% beneficial ownership limitation excluded, suggesting potential for further increases.

Risks

• Potential for increased market activity or volatility if Coastlands Capital decides to increase its stake or take a more active role.
• The exclusion of certain warrants from the reported beneficial ownership could imply future share acquisitions.
• The filing does not detail any specific strategic intentions, leaving room for speculation about future actions.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from iBio, Inc. It solely reports the beneficial ownership of securities by Coastlands Capital and related entities.

Management Comments

• Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry are filing jointly but not as members of a group, and each disclaims membership in a group.
• Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
• The Partnership holds the shares of Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares of Common Stock.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring stakes below a controlling threshold. This filing indicates Coastlands Capital's interest in iBio, Inc., a company operating in the biotechnology sector, which is characterized by significant research and development activities and potential for growth or volatility.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, indicating a passive investment approach by Coastlands Capital, which is typical for institutional investors acquiring stakes of this size (under 10%) in publicly traded companies.
• The 9.72% stake is a substantial minority holding, often seen as a precursor to potential influence or a significant long-term investment, but not a controlling interest like those typically held by activist investors (often >10-20%).
• Companies in the biotechnology sector, like iBio, Inc., often see such filings from investment firms specializing in healthcare and life sciences.

Stakeholder Impact

• Shareholders: May view the acquisition as a positive sign of institutional interest, potentially leading to increased liquidity or future strategic developments. However, the passive nature of the filing suggests no immediate change in control.
• Management: Will be aware of a significant minority shareholder and may engage with Coastlands Capital regarding company strategy or performance.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings by Coastlands Capital for any changes in beneficial ownership.
• Observe iBio, Inc.'s strategic developments and financial performance for potential impact from this significant shareholder.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the acquisition of a significant stake by an investment firm can be positive, the Schedule 13G indicates a passive investment approach without immediate strategic intent to influence control. The filing lacks specific operational or financial updates from iBio, Inc. itself, making it difficult to assess the company's underlying performance or future prospects solely from this document. Further analysis of iBio's business operations and financial health is required for a more definitive recommendation.

Keywords

iBio, Inc., Schedule 13G, Beneficial Ownership, Coastlands Capital, Investment, Securities, Common Stock, Stake Acquisition